## Jonathan G Pol

## List of Publications by Citations

Source: https://exaly.com/author-pdf/6393909/jonathan-g-pol-publications-by-citations.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73	3,417 citations	33	57
papers		h-index	g-index
89	4,309 ext. citations	8.7	5.34
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
73	Consensus guidelines for the detection of immunogenic cell death. <i>OncoImmunology</i> , <b>2014</b> , 3, e955691	7.2	524
72	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. Cancer Cell, 2016, 30, 147-160	24.3	285
71	First oncolytic virus approved for melanoma immunotherapy. <i>Oncolmmunology</i> , <b>2016</b> , 5, e1115641	7.2	181
70	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>OncoImmunology</i> , <b>2015</b> , 4, e1008866	7.2	162
69	Maraba virus as a potent oncolytic vaccine vector. <i>Molecular Therapy</i> , <b>2014</b> , 22, 420-429	11.7	106
68	Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies. <i>Trends in Immunology</i> , <b>2018</b> , 39, 209-221	14.4	96
67	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. <i>Nature Communications</i> , <b>2019</b> , 10, 1486	17.4	95
66	Trial watch: Peptide-based vaccines in anticancer therapy. <i>Oncolmmunology</i> , <b>2018</b> , 7, e1511506	7.2	90
65	Trial Watch:: Oncolytic viruses for cancer therapy. <i>Oncolmmunology</i> , <b>2014</b> , 3, e28694	7.2	88
64	HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. <i>Molecular Therapy</i> , <b>2013</b> , 21, 887-94	11.7	85
63	Trial Watch: Peptide-based anticancer vaccines. <i>Oncolmmunology</i> , <b>2015</b> , 4, e974411	7.2	81
62	Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. <i>Molecular Therapy</i> , <b>2014</b> , 22, 123-31	11.7	77
61	Trial Watch-Oncolytic viruses and cancer therapy. <i>Oncolmmunology</i> , <b>2016</b> , 5, e1117740	7.2	76
60	The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer. Cancers, 2019, 11,	6.6	54
59	Trial watch: Dendritic cell-based anticancer therapy. <i>OncoImmunology</i> , <b>2014</b> , 3, e963424	7.2	54
58	Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. <i>Cancer Immunology Research</i> , <b>2013</b> , 1, 309-19	12.5	54
57	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. <i>Immunological Reviews</i> , <b>2017</b> , 280, 165-174	11.3	52

56	Metabolic vulnerability of cisplatin-resistant cancers. EMBO Journal, 2018, 37,	13	52
55	Metabolic effects of fasting on human and mouse blood in vivo. <i>Autophagy</i> , <b>2017</b> , 13, 567-578	10.2	51
54	Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. <i>Oncolmmunology</i> , <b>2018</b> , 7, e1503032	7.2	50
53	Effects of interleukin-2 in immunostimulation and immunosuppression. <i>Journal of Experimental Medicine</i> , <b>2020</b> , 217,	16.6	46
52	Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8 T-cell responses to anticancer vaccines. <i>Oncolmmunology</i> , <b>2013</b> , 2, e26013	7.2	45
51	S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3. <i>Nature Immunology</i> , <b>2016</b> , 17, 514-522	19.1	45
50	Autophagy induction for the treatment of cancer. <i>Autophagy</i> , <b>2016</b> , 12, 1962-1964	10.2	44
49	Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 198, 218-25	7	42
48	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , <b>2020</b> , 11, 3819	17.4	41
47	Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity. <i>Cell Metabolism</i> , <b>2019</b> , 30, 754-767.e9	24.6	40
46	A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. <i>Oncolmmunology</i> , <b>2019</b> , 8, e1657375	7.2	38
45	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. <i>Oncolmmunology</i> , <b>2015</b> , 4, e985940	7.2	38
44	Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. <i>Oncolmmunology</i> , <b>2019</b> , 8, e1512329	7.2	38
43	Trial Watch: Radioimmunotherapy for oncological indications. <i>Oncolmmunology</i> , <b>2014</b> , 3, e954929	7.2	36
42	Trial Watch: DNA vaccines for cancer therapy. <i>Oncolmmunology</i> , <b>2014</b> , 3, e28185	7.2	33
41	Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses. <i>Blood</i> , <b>2013</b> , 121, 2432-9	2.2	31
40	Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. <i>EMBO Molecular Medicine</i> , <b>2020</b> , 12, e11622	12	31
39	Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models. <i>Methods in Molecular Biology</i> , <b>2019</b> , 1884, 297-315	1.4	31

38	Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination. <i>Journal of Immunology</i> , <b>2016</b> , 196, 4587-95	5.3	30
37	Customized Viral Immunotherapy for HPV-Associated Cancer. Cancer Immunology Research, <b>2017</b> , 5, 84	7 <del>1</del> 825 <del>9</del>	29
36	Trial watch: dietary interventions for cancer therapy. <i>Oncolmmunology</i> , <b>2019</b> , 8, 1591878	7.2	28
35	Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 654	8.4	27
34	Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy <b>2020</b> , 8,		24
33	Development and applications of oncolytic Maraba virus vaccines. <i>Oncolytic Virotherapy</i> , <b>2018</b> , 7, 117-12	2 <b>8</b>	24
32	Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl EKetoglutarate. <i>Cell Reports</i> , <b>2019</b> , 27, 820-834.e9	10.6	22
31	Trial watch: DNA-based vaccines for oncological indications. <i>Oncolmmunology</i> , <b>2017</b> , 6, e1398878	7.2	22
30	Anticancer effects of anti-CD47 immunotherapy. <i>OncoImmunology</i> , <b>2019</b> , 8, 1550619	7.2	19
29	Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts. <i>OncoImmunology</i> , <b>2018</b> , 7, e14	18 <sup>7</sup> 4 <del>9</del> 80	19
28	Alternative splicing-regulated protein of hepatitis B virus hacks the TNF-Estimulated signaling pathways and limits the extent of liver inflammation. <i>FASEB Journal</i> , <b>2015</b> , 29, 1879-89	0.9	17
27	Cytokines in oncolytic virotherapy. <i>Cytokine and Growth Factor Reviews</i> , <b>2020</b> , 56, 4-27	17.9	16
26	Tumor lysis with LTX-401 creates anticancer immunity. <i>OncoImmunology</i> , <b>2019</b> , 8, 1594555	7.2	14
25	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , <b>2021</b> , 11, 408-423	24.4	12
24	Tumor-intrinsic determinants of immunogenic cell death modalities. <i>OncoImmunology</i> , <b>2021</b> , 10, 18934	6 <b>%</b> .2	12
23	HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants. <i>Cell Reports</i> , <b>2018</b> , 24, 642-654	10.6	11
22	Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI). <i>Cell Death and Disease</i> , <b>2020</b> , 11, 502	9.8	10
21	Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning <b>2020</b> , 8,		10

## (2022-2020)

20	The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome. <i>Pharmacological Research</i> , <b>2020</b> , 161, 105	249 <sup>.2</sup>	8
19	Autophagy-mediated metabolic effects of aspirin. Cell Death Discovery, 2020, 6, 129	6.9	8
18	Immune contexture of cholangiocarcinoma. Current Opinion in Gastroenterology, 2020, 36, 70-76	3	8
17	Prospective comparison of Abbott RealTime HBV DNA and Versant HBV DNA 3.0 assays for hepatitis B DNA quantitation: impact on HBV genotype monitoring. <i>Journal of Virological Methods</i> , <b>2008</b> , 154, 1-6	2.6	7
16	Trial watch: intratumoral immunotherapy. <i>OncoImmunology</i> , <b>2021</b> , 10, 1984677	7.2	7
15	Metabolic Reprogramming by Reduced Calorie Intake or Pharmacological Caloric Restriction Mimetics for Improved Cancer Immunotherapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
14	Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination. <i>Methods in Molecular Biology</i> , <b>2020</b> , 2058, 191-211	1.4	5
13	Dynamical Boolean Modeling of Immunogenic Cell Death. Frontiers in Physiology, <b>2020</b> , 11, 590479	4.6	5
12	Repurposing CD8 T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?. <i>Oncolmmunology</i> , <b>2020</b> , 9, 1794424	7.2	5
11	Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,	16.6	4
10	Alternative splicing of viral transcripts: the dark side of HBV. Gut, 2021, 70, 2373-2382	19.2	3
9	Immunogenic Stress and Death of Cancer Cells in Natural and Therapy-Induced Immunosurveillance <b>2018</b> , 215-229		2
8	Oncolytic viruses: a step into cancer immunotherapy. Virus Adaptation and Treatment, 2011, 1		2
7	Improved Swiss-rolling method for histological analyses of colon tissue <i>MethodsX</i> , <b>2022</b> , 9, 101630	1.9	1
6	Circular RNAs as Potential Biomarkers in Breast Cancer Biomedicines, 2022, 10,	4.8	1
5	Local anesthetics elicit immune-dependent anticancer effects. <b>2022</b> , 10,		1
4	Beneficial autoimmunity links primary biliary cholangitis to the avoidance of cholangiocarcinoma. <i>Oncolmmunology</i> , <b>2021</b> , 10, 1968595	7.2	0
3	NAD+ depletion enhances reovirus-induced oncolysis in multiple myeloma <i>Molecular Therapy - Oncolytics</i> , <b>2022</b> , 24, 695-706	6.4	O

Une triade synergique de chimiothfapie, dihhibiteurs de points de contrle immunitaire et de mimfiques de la restriction calorique fadique des tumeurs dans un modie prolinique murin. HEGEL - HEpato-Gastro Entilologie Libiale, 2019, N° 4, 394

0.1

Valeur pronostique et pr@ictive de llmmunoscore dans les cancers du clon et de la vessie. *HEGEL - HEpato-GastroEntBologie LibBale*, **2021**, N° 2, 113-118

0.1